Order Article Reprints

Turla A, Laganà M, Abate A, Cremaschi V, Zamparini M, Chittò M, Consoli F, Alberti A, Ambrosini R, Tamburello M, et al. Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status. Cancers. 2023; 15(18):4491. https://doi.org/10.3390/cancers15184491

Turla, Antonella, Marta Laganà, Andrea Abate, Valentina Cremaschi, Manuel Zamparini, Matteo Chittò, Francesca Consoli, Andrea Alberti, Roberta Ambrosini, Mariangela Tamburello, and et al. 2023. "Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status" Cancers 15, no. 18: 4491. https://doi.org/10.3390/cancers15184491

Turla, A., Laganà, M., Abate, A., Cremaschi, V., Zamparini, M., Chittò, M., Consoli, F., Alberti, A., Ambrosini, R., Tamburello, M., Grisanti, S., Tiberio, G. A. M., Sigala, S., Cosentini, D., & Berruti, A. (2023). Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status. Cancers, 15(18), 4491. https://doi.org/10.3390/cancers15184491